H.C. Wainwright lowered the firm’s price target on Caribou Biosciences to $23 from $25 and keeps a Buy rating on the shares. The analystd says the updated ANTLER trial results continue to appear promising despite a relatively small sample size.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRBU:
- Caribou Biosciences’ data in LBCL looks ‘solid,’ says Truist
- Caribou Biosciences 19.23M share Spot Secondary priced at $6.50
- Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering
- Caribou: Follow-up data from Antler trial suggest CB-010 tolerated in r/r B-NHL
- Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
